Latest Breaking News On - Hase 2b sunrise 1 trial nct04640623 - Page 1 : comparemela.com

Andrea Necchi, MD, discusses results from the phase 2b SunRISe-1 trial of TAR-200 in patients with Bacillus Calmette-Guérin (BCG)–unresponsive, high-risk, non–muscle-invasive bladder cancer.

Andrea necchiSalute san raffaele universityScientific instituteGenitourinary medical oncologyRaffaele hospitalVita salute san raffaele universityBacillus calmette guHase 2b sunrise 1 trial nct04640623Tar 200Bacillus calmette guérin bcg unresponsiveHigh riskNon muscle invasive bladder cancer